BRIEF-Zelira Therapeutics Ltd - Meets Primary Endpoints For Phase (1B2A) Medicinal Cannabis Trial For Insomnia1 Min ReadFeb 19 (Reuters) - Zelira Therapeutics Ltd: * MEETS PRIMARY ENDPOINTS FOR PHASE (1B/2A) MEDICINAL CANNABIS TRIAL FOR INSOMNIA Source text reut.rs/2vPA97p Further company coverage:All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.(c) 2020 Reuters. All Rights Reserved.